Jane Street Group LLC Cuts Stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Jane Street Group LLC trimmed its position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 65.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 24,336 shares of the company’s stock after selling 46,754 shares during the quarter. Jane Street Group LLC’s holdings in Maravai LifeSciences were worth $133,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of MRVI. SG Americas Securities LLC grew its position in Maravai LifeSciences by 7.3% during the 4th quarter. SG Americas Securities LLC now owns 33,046 shares of the company’s stock valued at $180,000 after purchasing an additional 2,239 shares during the last quarter. Bleakley Financial Group LLC grew its position in Maravai LifeSciences by 30.1% during the 4th quarter. Bleakley Financial Group LLC now owns 41,691 shares of the company’s stock valued at $227,000 after purchasing an additional 9,657 shares during the last quarter. Empowered Funds LLC purchased a new stake in Maravai LifeSciences during the 4th quarter valued at about $155,000. Rhumbline Advisers grew its position in Maravai LifeSciences by 9.9% during the 4th quarter. Rhumbline Advisers now owns 185,221 shares of the company’s stock valued at $1,009,000 after purchasing an additional 16,712 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd grew its position in Maravai LifeSciences by 155.9% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 32,359 shares of the company’s stock valued at $176,000 after purchasing an additional 19,713 shares during the last quarter. 50.25% of the stock is owned by hedge funds and other institutional investors.

Maravai LifeSciences Stock Performance

MRVI opened at $2.39 on Friday. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. The company has a market cap of $608.64 million, a price-to-earnings ratio of -1.46 and a beta of 0.25. The company’s 50 day moving average is $2.05 and its 200 day moving average is $3.62. Maravai LifeSciences Holdings, Inc. has a 12-month low of $1.67 and a 12-month high of $10.03.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The business had revenue of $46.85 million during the quarter, compared to analysts’ expectations of $44.01 million. Maravai LifeSciences had a negative return on equity of 6.61% and a negative net margin of 81.13%. Maravai LifeSciences’s revenue for the quarter was down 26.9% compared to the same quarter last year. On average, equities research analysts predict that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on MRVI. Craig Hallum reduced their price target on shares of Maravai LifeSciences from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, May 13th. Morgan Stanley reduced their price target on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research note on Tuesday, March 25th. Bank of America reduced their price target on shares of Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. UBS Group reduced their price target on shares of Maravai LifeSciences from $8.00 to $2.50 and set a “neutral” rating for the company in a research note on Friday, March 21st. Finally, Stifel Nicolaus set a $5.00 price target on shares of Maravai LifeSciences in a research note on Friday, March 21st. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $6.64.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.